

Mary Washington Hospital

MediCorp

1001 Sam Perry Boulevard
Fredericksburg, VA 22401
(540) 741-1100

22 May 2007

U.S. Nuclear Regulatory Commission
Region I
475 Allendale Road
King of Prussia, Pennsylvania
19406-1415

NMSSB1

03008082

RE: NRC Material License 45-00935-02

Dear Sir or Madam:

Please amend the above referenced license to add John C. Chinault, MD for - 35.100, 35.200, and 35.300 and 35.400. Dr. Chinault was an authorized user for medical use at Petersburg Hospital Company, LLC (d/b/a Southside Regional Medical Center), and license number 45-00317-02. Dr. Chinault is authorized on Petersburg Hospital Company for all Byproducts, sources, and/or special nuclear material requested in this letter.

If you have any questions or if I may be of further assistance, please contact me at your convenience.

Sincerely,



Linda Prowett, BLS, CNMT, NCT
Radiation Safety Officer
540-741-1580



Paul Prewitt
Vice President,
Ambulatory Services and Properties

RECEIVED
REGION 1

2007 MAY 29 PM 1:20

140566

NMSS/RGN1 MATERIALS-002

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Petersburg Hospital Company, LLC d/b/a Southside Regional Medical Center</p> <p>2. 801 South Adams Street Petersburg, Virginia 23803</p>	<p>In accordance with the application dated September 28, 2005,</p> <p>3. License number 45-00317-02 is amended in its entirety to read as follows:</p> <p>4. Expiration date March 31, 2016</p> <p>5. Docket No. 030-03301 Reference No.</p>
--	---

6. Byproduct, source, and/or special nuclear material

A. Any byproduct material permitted by 10 CFR 35.100

B. Any byproduct material permitted by 10 CFR 35.200

C. Any byproduct material permitted by 10 CFR 35.300

D. Any byproduct material permitted by 10 CFR 35.400

E. Any byproduct material permitted by 10 CFR 31.11

7. Chemical and/or physical form

A. Any

B. Any

C. Any

D. Sealed Sources (North American Scientific, Inc. Model MED3631; Mills Biopharmaceuticals, Inc. Model I-125 SL)

E. Prepackaged Kits

8. Maximum amount that licensee may possess at any one time under this license

A. As needed

B. As needed

C. 1 curie

D. 1 curie

E. 10 millicuries

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

D. Any manual brachytherapy procedure permitted by 10 CFR 35.400, for which the patient can be released under the provisions of 10 CFR 35.75.

E. In vitro studies.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
45-00317-02

Docket or Reference Number
030-03301

Amendment No. 51

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 801 South Adams Street, Petersburg, Virginia.
11. The Radiation Safety Officer for this license is John C. Chinault, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

William P. Baker, M.D.	35.100; 35.200
Ray A. Beauchamp, M.D.	35.100; 35.200
Russell O. Briere, M.D.	35.100; 35.200
John C. Chinault, M.D.	35.100; 35.200; 35.300; 35.400
Charles H. Cockrell, M.D.	35.100; 35.200
Sonia Crimaldi, M.D.	35.100; 35.200
Kieran M. Gorman Cross, M.D.	35.100; 35.200
W. Scott Cunningham, M.D.	35.100; 35.200
Nathaniel W. Cuthbert, M.D.	35.100; 35.200
Elizabeth A. Dawson, M.D.	35.100; 35.200; 35.300
Melanie Ann Fidler, M.D.	35.100; 35.200
Robert Y. Fidler, M.D.	35.100; 35.200
R. Westwood Fuller, M.D.	35.100; 35.200
Alexander K. Girevendulis, M.D.	35.100; 35.200
Lowrey H. Holthaus, M.D.	35.100; 35.200
Jeffrey E. Hull, M.D.	35.100; 35.200
Julius Hurwitz, M.D.	35.100; 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
45-00317-02Docket or Reference Number
030-03301


Amendment No. 51

<u>Authorized Users</u>	<u>Material and Use</u>
A. John Kuta, M.D.	35.100; 35.200
George W. Martin, Jr., M.D.	35.100; 35.200
David A. May, M.D.	35.100; 35.200
Phillip H. McClure, M.D.	35.100; 35.200; 35.300 except iodine-131; <u>in vitro</u> studies
Carlisle Lee Morgan, M.D.	35.100; 35.200
Jeffrey Todd Morgan, M.D.	35.100; 35.200
Joel F. Parker, M.D.	35.100; 35.200
Vasundhara Raval, M.D.	35.100; 35.200
Gerry L. Reece, M.D.	35.100; 35.200
Efstathios Spinos, M.D.	35.100; 35.200
Cary Straton, M.D.	35.100; 35.200; <u>in vitro</u> studies
Timothy R. Taylor, M.D.	35.100; 35.200
J. Keith Thompson, M.D.	35.100; 35.200
Taryn G. Torre, M.D.	35.300; 35.400
Thomas E. Underhill, D.D.S., M.S., M.D.	35.100; 35.200
James A. Urso, M.D.	35.100; 35.200
James D. Wadsworth, M.D.	35.100; 35.200
William E. Wheeler, M.D.	35.100; 35.200
Steven M. Wiebe-King, M.D.	35.200
B. Gerald Yount, Jr., M.D.	35.100; 35.200
James J. Zelenak, M.D.	35.100; 35.200
Craig D. McCormick, M.D.	35.100; 35.200
Matthew L. Cohen, M.D.	35.100; 35.200
David M. Randolph, M.D.	35.400

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
45-00317-02Docket or Reference Number
030-03301

Amendment No. 51

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated September 28, 2005 (ML052800359)
- B. Letter dated February 14, 2006 (ML060670083)



For the U.S. Nuclear Regulatory Commission

Date March 9, 2006

By

Sandra Gabriel
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406

Thursday, March 09, 2006 1:25:49 PM

This is to acknowledge the receipt of your letter/application dated

5/22/2007, and to inform you that the initial processing which includes an administrative review has been performed.

☒ AMEND. 45-00835-02
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

☐ Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned Mail Control Number 140566.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.